

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 April 2020 (23.04.2020)



(10) International Publication Number
WO 2020/079086 A1

(51) International Patent Classification:

A61P 37/06 (2006.01) C07K 16/28 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2019/078093

(22) International Filing Date:

16 October 2019 (16.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/746,174 16 October 2018 (16.10.2018) US

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **BROCK, Melissa Kaye**; c/o UCB Biosciences Inc, 8010 Arco Corporate Drive, Raleigh, North Carolina 27617 (US). **BYRNES, William James**; c/o UCB Biosciences Inc, 8010 Arco Corporate Drive, Raleigh, North Carolina 27617 (US). **GREVE, Bernhard Heinrich**; c/o IPD, UCB Biosciences GmbH, Alfred-Nobel-Strasse, 10, 40789 Monheim am Rhein (DE). **KIESSLING, Claus**

Peter; c/o IPD, UCB Biosciences GmbH, Alfred-Nobel-Strasse, 10, 40789 Monheim am Rhein (DE). **LANGDON, Grant**; c/o Advantage Resourcing, Matrix House, Basing View, Basingstoke Hampshire RG21 4FF (GB). **WEBSTER MANIS, Elizabeth**; c/o UCB Biosciences Inc, 8010 Arco Corporate Drive, Raleigh, North Carolina 27617 (US).


(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS

Figure 4



(57) Abstract: The disclosure relates to a method of treating or preventing Myasthenia Gravis (MG) in a human in need thereof using an anti-FcRn antibody or antigen binding fragment thereof. In particular, the method provides suitable dosage regimens for such treatment.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*